Select Page

Takeda’s dengue vaccine candidate’s filing packages has been accepted by the European Medicines Agency (EMA), which is being investigated for its prevention of dengue in individuals between the ages of 4 and 60. Takeda also submitted the vaccine for regulatory approval to dengue-epidemic countries like Malaysia, Singapore, Mexico, Indonesia, Colombia, Brazil, Sri Lanka, Argentina, and Thailand through the first-ever parallel assessment of the use of the medicinal product in the European Union through the EU-M4all procedure. Derek Wallace, VP, Dengue Global Program Leader at Takeda, stated, “Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. With limited options to prevent the disease, there is a pressing need for widely available dengue vaccines. Takeda is committed to working with regulatory authorities and recommending bodies to support evaluation of our submissions and achieve access for TAK-003.”

Read more here.

More on: